SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CVTX - CV Therapeutics, Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Haynes who wrote (94)8/4/2003 11:52:54 PM
From: Miljenko Zuanic   of 411
 
Jim,

It is a long story, going back to 98/99/00, and early. R was tested for stable chronic angina as monotherapy and in combination with other anti-angina drugs. Both trials was too small for any sub-group analysis, imo. However, CVTX identify diabetic as those who benefit the most (high blood glucose level, make sense).

To make things clear (from my perspective and without going into depth, take it as is or ignore) I do not see good chance for approval without running large new PIII trial in US ALONE.

Miljenko

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News